TCBP Announces Transition from Nasdaq to OTC Markets
TC BioPharm (NASDAQ: TCBP) announced its delisting from the Nasdaq Stock Market due to non-compliance with the minimum bid price requirement of $1.00 per share. The company received the delisting notice on March 20, 2025, from the Nasdaq Hearings Panel.
Trading of TCBP securities will be suspended on Nasdaq effective March 24, 2025, with an expected transition to OTC Markets on the same day. Management is currently pursuing an appeal with Nasdaq. Despite the exchange transition, TC BioPharm will maintain its SEC filing obligations for annual reports and other required documentation.
The clinical-stage biotechnology company, which develops platform allogeneic gamma-delta T cell therapies for cancer and other indications, affirmed its commitment to continuing its research, clinical trials, and therapeutic development initiatives.
TC BioPharm (NASDAQ: TCBP) ha annunciato la sua esclusione dal Nasdaq Stock Market a causa della non conformità con il requisito del prezzo minimo di offerta di $1,00 per azione. La società ha ricevuto la notifica di esclusione il 20 marzo 2025, dal Nasdaq Hearings Panel.
Il trading dei titoli TCBP sarà sospeso su Nasdaq a partire dal 24 marzo 2025, con una transizione prevista a OTC Markets lo stesso giorno. La direzione sta attualmente perseguendo un appello con Nasdaq. Nonostante la transizione dell'exchange, TC BioPharm manterrà i suoi obblighi di deposito SEC per relazioni annuali e altra documentazione richiesta.
La società biotecnologica in fase clinica, che sviluppa terapie a base di cellule T gamma-delta allogeniche per il cancro e altre indicazioni, ha ribadito il suo impegno a continuare la sua ricerca, prove cliniche e iniziative di sviluppo terapeutico.
TC BioPharm (NASDAQ: TCBP) anunció su exclusión del Nasdaq Stock Market debido a la falta de cumplimiento con el requisito de precio mínimo de oferta de $1.00 por acción. La compañía recibió la notificación de exclusión el 20 de marzo de 2025, del Nasdaq Hearings Panel.
La negociación de valores de TCBP se suspenderá en Nasdaq a partir del 24 de marzo de 2025, con una transición esperada a OTC Markets el mismo día. La dirección está actualmente apelando ante Nasdaq. A pesar de la transición del intercambio, TC BioPharm mantendrá sus obligaciones de presentación ante la SEC para informes anuales y otra documentación requerida.
La compañía biotecnológica en etapa clínica, que desarrolla terapias de células T gamma-delta alogénicas para el cáncer y otras indicaciones, reafirmó su compromiso de continuar su investigación, ensayos clínicos e iniciativas de desarrollo terapéutico.
TC BioPharm (NASDAQ: TCBP)는 주당 최소 입찰 가격 요구 사항인 $1.00을 준수하지 않아 Nasdaq 증권 거래소에서 상장 폐지되었다고 발표했습니다. 회사는 2025년 3월 20일 Nasdaq 청문 위원회로부터 상장 폐지 통지를 받았습니다.
TCBP 증권의 거래는 2025년 3월 24일부터 Nasdaq에서 중단되며, 같은 날 OTC Markets로의 전환이 예상됩니다. 경영진은 현재 Nasdaq에 항소를 진행 중입니다. 거래소 전환에도 불구하고 TC BioPharm은 연례 보고서 및 기타 필수 문서에 대한 SEC 제출 의무를 유지할 것입니다.
암 및 기타 적응증을 위한 동종 이식 감마 델타 T 세포 치료제를 개발하는 임상 단계 생명공학 회사는 연구, 임상 시험 및 치료 개발 이니셔티브를 계속할 것임을 확언했습니다.
TC BioPharm (NASDAQ: TCBP) a annoncé son retrait du Nasdaq Stock Market en raison du non-respect de l'exigence de prix d'offre minimum de 1,00 $ par action. La société a reçu l'avis de retrait le 20 mars 2025, du Nasdaq Hearings Panel.
Le trading des titres TCBP sera suspendu sur Nasdaq à partir du 24 mars 2025, avec une transition prévue vers OTC Markets le même jour. La direction poursuit actuellement un appel auprès de Nasdaq. Malgré cette transition, TC BioPharm maintiendra ses obligations de dépôt auprès de la SEC pour les rapports annuels et autres documents requis.
L'entreprise biopharmaceutique en phase clinique, qui développe des thérapies cellulaires T gamma-delta allogéniques pour le cancer et d'autres indications, a réaffirmé son engagement à poursuivre ses recherches, essais cliniques et initiatives de développement thérapeutique.
TC BioPharm (NASDAQ: TCBP) gab bekannt, dass es aufgrund der Nichteinhaltung der Mindestgebotsanforderung von $1,00 pro Aktie vom Nasdaq Stock Market ausgeschlossen wird. Das Unternehmen erhielt die Mitteilung über die Delistung am 20. März 2025 vom Nasdaq Hearings Panel.
Der Handel mit TCBP-Wertpapieren wird ab dem 24. März 2025 an der Nasdaq ausgesetzt, mit einer erwarteten Übergabe zu OTC Markets am selben Tag. Das Management verfolgt derzeit einen Einspruch bei Nasdaq. Trotz des Wechsels der Börse wird TC BioPharm seine SEC-Meldepflichten für Jahresberichte und andere erforderliche Dokumente aufrechterhalten.
Das biopharmazeutische Unternehmen in der klinischen Phase, das allogene gamma-delta T-Zelltherapien für Krebs und andere Indikationen entwickelt, bekräftigte sein Engagement, seine Forschungs-, klinischen Test- und therapeutischen Entwicklungsinitiativen fortzusetzen.
- Company maintains SEC reporting requirements, ensuring continued transparency
- Clinical trials and therapeutic development initiatives continue unaffected
- Delisting from Nasdaq due to failure to maintain $1.00 minimum share price
- Downgrade to less prestigious OTC Markets trading
- Potential reduction in stock liquidity and institutional investor access
- Failed to meet listing compliance despite previous warnings
The Company's securities will be suspended for trading on Nasdaq effective at the opening of trading on Monday, March 24, 2025. The Company expects its American Depositary Shares to be eligible to trade on the OTC Markets effective with the opening of trading on Monday, March 24, 2025. This delisting and transition to the OTC Markets will not change the Company's obligation to file annual reports and certain other reports with the SEC under the applicable federal securities laws. The Company cautions the reader to read this press release in its entirety and refer to the Company's press releases and reports filed with the SEC, including the risks and uncertainties discussed therein, before making any investment decision.
TC BioPharm remains fully committed to advancing its innovative research, clinical trials, and therapeutic development initiatives.
About TC BioPharm (Holdings) PLC
TC BioPharm is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gamma-delta T-cell therapies for cancer treatment with human efficacy data in acute myeloid leukemia. Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems and can intrinsically differentiate between healthy and diseased tissue.
TC BioPharm is the leader in developing gamma-delta T cell therapies and the first company to conduct phase II/pivotal clinical studies in oncology. The Company is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line - Phase 2b/3 pivotal trial in the treatment of acute myeloid leukemia using the Company's proprietary allogeneic CryoTC technology to provide frozen product to clinics worldwide.
Forward-Looking Statements for TC BioPharm
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the Company's intent or ability to affect any budget savings or execute on any M&A or capital raising strategy. These statements are based on management's current assumptions and are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. For other important factors that could cause actual results to differ materially from the forward-looking statements in this Current Report on Form 8-K, please see the risks and uncertainties identified under the heading "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2023, and our other reports filed with the SEC, all of which is available on the Company's Investor Relations website at www.tcbiopharm.com and on the SEC website at www.sec.gov. All forward-looking statements reflect the Company's beliefs and assumptions only as of the date of this Current Report on Form 8-K. The Company undertakes no obligation to update forward-looking statements to reflect future events or circumstances.
View original content to download multimedia:https://www.prnewswire.com/news-releases/tcbp-announces-transition-from-nasdaq-to-otc-markets-302408102.html
SOURCE TC BioPharm
FAQ
When will TCBP stock be delisted from Nasdaq?
Why is TCBP being delisted from Nasdaq?
Where will TCBP stock trade after Nasdaq delisting?
Will TCBP still file reports with the SEC after delisting?
